Anika Therapeutics (ANIK) Short term Debt (2010 - 2022)

Anika Therapeutics (ANIK) has 7 years of Short term Debt data on file, last reported at $4.3 million in Q2 2022.

• Short term Debt for Q2 2022 came in at $4.3 million, down 74.42% year-over-year; the trailing twelve-month figure through Jun 2022 was $4.3 million (down 74.42% YoY), and the FY2021 annual result was $4.3 million, down 67.04% from the prior year.
• Short term Debt held at $4.3 million in Q2 2022 per ANIK's latest filing, from $4.3 million in the prior quarter.
• Over five years, Short term Debt peaked at $24.8 million in Q1 2021 and troughed at $4.3 million in Q3 2021.
• A 3-year average of $10.3 million and a median of $4.3 million in 2021 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2021 and 2022: Short term Debt plunged 67.04% in 2021, then plunged 82.68% in 2022.
• A 3-year view of Short term Debt shows it stood at $13.1 million in 2020, then sank by 67.04% to $4.3 million in 2021, then changed by 0.0% to $4.3 million in 2022.
• Business Quant data shows ANIK's Short term Debt at $4.3 million in Q2 2022, $4.3 million in Q1 2022, and $4.3 million in Q4 2021.